Reported Thursday, Pendopharm Partners With Ascendis Pharma For Exclusive Distribution of TransCon™ PTH In Canada
Under the terms of the agreement, Pendopharm is responsible for regulatory approval and commercialization of Ascendis' hypoparathyroidism treatment TransConTM PTH (palopegteriparatide) in Canada. Financial terms of the agreement are not disclosed.